Explore

Trendline Trendline
Bracco Imaging Introduces BubbleGen Early Access Program for Cell Therapy Innovation

Bracco Imaging Introduces BubbleGen Early Access Program for Cell Therapy Innovation

Bracco Imaging Introduces BubbleGen Early Access Program for Cell Therapy Innovation
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing

Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing

Epicrispr and Forge Biologics Partner for AAV Development and Manufacturing
Trendline Trendline
Bracco Launches BubbleGen Early Access Program for Cell Therapy Innovation

Bracco Launches BubbleGen Early Access Program for Cell Therapy Innovation

Bracco Launches BubbleGen Early Access Program for Cell Therapy Innovation
Trendline Trendline
Eascra Biotech Expands Expertise with Dr. Anne Yau to Advance RNA Therapeutics

Eascra Biotech Expands Expertise with Dr. Anne Yau to Advance RNA Therapeutics

Eascra Biotech Expands Expertise with Dr. Anne Yau to Advance RNA Therapeutics
Trendline Trendline
Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill

Connecticut Biopharmaceutical Company Reports Promising Results for Experimental Hair Loss Pill
Trendline Trendline
Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy

Epicrispr and Forge Biologics Partner for AAV Manufacturing in Muscular Dystrophy Therapy
Trendline Trendline
Eascra Biotech Appoints Dr. Anne Yau to Advance RNA Therapeutics for Musculoskeletal Diseases

Eascra Biotech Appoints Dr. Anne Yau to Advance RNA Therapeutics for Musculoskeletal Diseases

Eascra Biotech Appoints Dr. Anne Yau to Advance RNA Therapeutics for Musculoskeletal Diseases
Trendline Trendline
Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals

Arrowhead Pharmaceuticals Licenses RNAi Therapeutic for MASH to Madrigal Pharmaceuticals
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutic IP

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutic IP

Lunai Bioworks Secures $20 Million to Enhance CNS Drug Delivery and Neurotherapeutic IP
Trendline Trendline
GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe

GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe

GRIN Therapeutics Expands Phase 3 Beeline Study for GRIN-NDD in Europe